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Nineteen percent ofthe approximately 30,000 members ofthe Yale community aged 18 through 59 received
swine influenza monovalent vaccine (A/New Jersey/ 1976) during the three days of a mass immunization
program in Nov. 1976. Based on 1508 card questionnaires received, 71.2 percent of the vaccine recipients
experienced a sore arm, 23.4 percent headache, 13.4 percent chilliness, and 9.7 percent feverishness or fever.
The sore arm was judged as severe in 5.9 percent as was the headache in 4.2 percent. Other reactions were
regarded as severe in less than 2 percent. All reactions were reported more commonly by women than men
and all decreased with age.
Serologic tests carried out at the start of the immunization period revealed that influenza A/New
Jersey/ 1976 antibody was absent from 78.6 percent of the recipients; almost all persons under 25 lacked this
antibody. A significant antibody rise occurred in 78.3 percent of those receiving a single dose of monovalent
vaccine. Somewhat better antibody responses occurred in 36-59 year olds than in those age 17-25 (84.9 vs
75.5 percent); the geometric mean antibody titer was also much higher (1:136.8 vs 1:31.2). However, the
presence of pre-existing homologous antibody did not significantly improve the antibody response to the
vaccine. Cross-reacting antibody rises to A/Victoria/ 1975 were found in 16.2 percent of the recipients of
monovalent vaccine.
The isolation of an influenza strain in recruits at Fort Dix, NewJersey inJanuary,
1976 [1] that bore surface markers similar to the great pandemic strain of 1918 was
deemed of much importance for several reasons. First, the 1918 outbreak was one of
the most severe affecting mankind with an estimated death toll of some 20 million
persons worldwide and over 1/2 million in the United States [2]. The death rate was
especially high in young adults. The morbidity from the disease was about 500
million cases-over 1/2 the world's population fell ill. While it was not possible to
measure whether the New Jersey isolate would have the same pathogencity and
virulence as the 1918 strain, the identity of the specific hemagglutinin and neur-
aminidase suggested this potential. Second, while swine influenza virus has produced
illness in pigs since 1918 with occasional sporadic human cases, the Fort Dix
outbreak was the first recognized example of person-to-person spread, involving
some 500 persons. Whether this was due to the acquisition of a new spreading
potential, or simply represented the enhanced transmission of a strain of low
virulence in the closed environment of recruit training was a highly important but
unanswerable question. Third, there appeared to be sufficient time to prepare and
administer a swine flu vaccine before the next winter season. On the advice of the
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Influenza Advisory Committee to the Public Health Service the Director of the
Center for Disease Control proposed that a nationwide program for all ages be
instituted. The scientific, political, and financial bases for this decision and the
problems encountered in its implementation are, and will continue to be, a matter of
vigorous debate. (See Osborn, J, ed., Influenza in American 1918-1976, N.Y.,
Prodist, 1976, and the Nov.-Dec. 1977 issue of the Yale J. Biol. & Med.)
In response to this directive the members of the Yale University Health Plan and of
the New Haven community were offered the swine flu vaccine in a mass immuniza-
tion program. Information describing the vaccine and an informed consent card were
given to each individual. The vaccine was administered over a 3 day period in the
Yale Gymnasium using jet injection guns. Since data on the vaccine was limited to
field trials carried out largely in young adults the current investigation was initiated
to determine the acceptance rate, the reaction rate and the immunological response in
a broad age group.
MATERIALS AND METHODS
The Population: The Yale University Health Plan offered the Swine Influenza
Immunization Program to the entire Yale University Community of about 30,000
persons. The Yale Health Plan itself enrolls about 20,000 of these, including students,
faculty, employees, and their families.
The Vaccine: A whole monovalent vaccine prepared by Merrell-National Labora-
tories containing 200 chicken cell agglutinating (CCA) units of the A / New Jersey
1976 strain of influenza vaccine was used in adults, ages 18-59. A bivalent vaccine
also manufactured by Merrell-National Laboratories containing 200 CCA units of
the same swine influenza strain and 200 CCA units of A2 / Victoria/ 1975 strain was
given to persons 60 years old and over and to high risk groups, such as persons with
chronic cardiac or pulmonary diseases. The monovalent vaccine was given byjet gun
in the Yale University Gymnasium and the bivalent by needle and syringe. A single
0.5 ml dose of each was given subcutaneously in the arm.
Questionnaire: A short anonymous questionnaire was prepared on a postcard to be
returned by Campus (free) mail which requested information on the occurrence and
severity of reactions within 48 hours of receiving the influenza vaccine. The reactions
itemized were fever (feverishness), headache, chilliness, muscle aches, and sore arm.
A space was left to record other reactions. The age and sex of the respondent was
requested. The cards were distributed randomly to 2,000 persons.
Serological studies: An initial serum sample was obtained on the day ofimmuniza-
tion from 387 volunteers of all ages (16-70). A follow-up sample was successfully
obtained 3 to 4 weeks later from 269 of the same persons (71.5 percent): 222 of these
had received monovalent and 47 bivalent vaccine. The hemagglutination-inhibition
titers to A / New Jersey/ 1976, A2 / Victoria / 1975, and B / Hong Kong / 1972 were
measured on microtiter plates after treatment of the serum with receptor destroying
enzyme. The methods employed were those recommended by the Center for Disease
Control. The diluents were added and the dilutions were made using automated
equipment (Cooke Engineering Co.). Positive and negative controls were included in
each test. All questionable results were repeated. The geometric mean antibody titer
was based on sera with a titer of 1:10 or higher.
RESULTS
Vaccine Acceptance
The immunization program was offered on November 10, 11 and 12th, 1976 in the
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Payne-Whitney Gymnasium of Yale University to some 30,000 persons in the Yale
community. Special risk, pediatric, and athletic groups were immunized separately
during November in the outpatient clinic of the Yale Health Service. In all, 5674
doses of monovalent and 1763 of bivalent vaccine were given. The 7437 persons
receiving vaccine represents 25 percent of the Yale community. Based on the age
distribution of persons enrolled in the Yale Health Plan, about 19 percent were
immunized with monovalent vaccine in the 18 through 59 age group duringthe 3 day
period.
Reactions to Vaccine
Seventy-seven percent (1540) of 2,000 questionnaire cards distributed were re-
turned. An analysis was made of 1508 of these on which the appropriate items had
been filled out; this represented 757 females and 751 males. The overall reactions are
tabulated by sex in Table 1. Seventy-one percent of recipients reported soreness of
the arm at the site of the jet injection of monovalent vaccine but only 5.9 percent
classified this as severe. Sore arms were reported by 81 percent of females and 57.2
percent of males. Headache and muscle aches were recorded with about equal
frequency in both sexes (22 to 24 percent), but were rarelyjudged as severe. Chilliness
was reported by 8.9 percent of males and 17.9 percent offemales; less than 2 percent
of either sex felt it was severe. The occurrence offever or feverishness was noted on
9.7 percent of the cards, 6.8 percent by males, and 11.0 percent by females; only 0.2
percent felt it was more than ofslight degree. Other symptoms mentioned as present
included fatigue in 5.1 percent, nausea in 3.1 percent, and itching in 1.1 percent
(Table 2).
Analysis ofthe questionnaire results by age and sex is given in Fig. 1. In general, all
reactions decreased with increasing age and all were more common in females than in
TABLE I
Reactions to Influenza Vaccine Among 1508 Recipients (757 females, 751 males)
Who Returned the Questionnaire Card
Percent Reporting Reaction
Female Male Total
Fever Slight (<1000F) 9.8 6.0 7.9
Moderate (100-100.9°F) 0.8 0.8 1.6
Severe (103°F) 0.4 0 0.2
11.0 6.8 9.7
Headache Moderate 21.4 16.9 19.2
Severe 4.2 0 4.2
25.6 16.9 23.4
Chilliness Moderate 16.1 8.1 12.1
Severe 1.8 0.8 1.3
17.9 8.9 13.4
Muscle Aches Moderate 25.3 16.4 20.8
Severe 2.8 0.7 1.8
28.1 17.1 22.6
Sore Arm Moderate 70.6 55.9 65.3
Severe 10.4 1.3 5.9
81.0 57.2 71.2
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T-ABLE 2
Other Symptoms Mentioned
Number % of Total
Fatigue F 44 5.8
M 33 4.4
77 5.1
Nausea F 35 4.6
M _1 1.5
46 3.1
Itching F 9 1.2
M 8 1.1
17 1.1
# Female 55 187 184 83
# Male 64 196 181 91
63 40 38 50 47 10 757
45 42 31 39 46 16 751
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FIG. 1a,b. Frequency of fever (upper panel) and headache (lower panel) according to age and sex.
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FIG. Ic,d. Frequency of chilliness (upper panel) and muscle aches (lower panel) by age and sex.
males at any age. The decrease with increasing age was most marked for the
symptoms of sore arm (Fig. le) and muscle aches (Fig. Id). However, males in the
15-19 age group complained less commonly of sore arm and of muscle aches than
males in the 20-24 bracket; this was not observed in females. An interesting and
unexplained phenomenon was the occurrence of a sharp peak in the complaint of
headaches starting in 30-34 year old females which increased from 20 percent to 40
percent at age 40-44 (Fig. lb). Since the questionnaire cards were returned anony-
mously, it was not possible to correlate the occurrence of the reactions with the
presence or absence ofpre-existing antibody to swine influenza. However, the overall
results for antibody tests given in the next section is consistent with the view that
vaccine reactions were less common in persons with pre-existing antibody.
The occurrence of one or more reactions in the same person was analyzed by sex
and is shown in Table 3. The percent offemales reporting one or more reactions was
consistently higher than in males and increased with the number of reactions. For
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FIG. le. Frequency of sore arm by age and sex.
example, 26.6 percent of females reported 3 or more reactions vs. 16.4 percent in
males and twice as many females as males reported 5 or more reactions.
Pre-existing Antibody
Hemagglutinin-inhibition (HI) antibody to A/New Jersey/ 1976, A/Victoria/ 1975
and B/Hong Kong/ 1972 antigens was measured in the sera of271 persons on the day
that swine influenza vaccine was administered to determine pre-existing antibody
titers.
The percent of sera lacking antibody to various antigens at the lowest dilution
tested (1:10) is shown by age groups in Table 4. Antibody to the A/NJ/76 swine flu
antigen was absent in 99.1 percent of persons tested under age 25 (mostly age 18-25)
but gradually appeared with increasing age so that 55 percent lacked antibody age
36-59 and none of the 9 sera age 60 or over lacked antibody. In the 18 through 59
target age group for the swine flu vaccine 84.3 percent lacked antibody to this virus.
Antibody to the A/Victoria/75 strain was absent in 56 percent ofthe 271 sera tested,
more often so in the older age groups. Antibody to the B/Hong Kong/72 virus was
absent in 57.6 percent of the total group and about equally in age groups up through
59.
Humoral Antibody Responses
Paired sera taken at the time of immunization and 3-4 weeks later from 222
TABLE 3
Cumulative Frequency of Multiple Vaccine Reactions
No. Percent with I to 5 reactions
>1 >2 >3 >4 >5
Male 746 73.1 32.1 16.4 8.2 3.1
Female 812 84.2 44.6 26.6 13.8 6.5
Ratio M:F 1:1.5 1:1.4 1:1.6 1:1.7 1:2.1INFLUENZA IMMUNIZATION IN YALE COMMUNITY
TABLE 4
Percent Lacking HI Antibody at <1:10 to A/New Jersey/76, A/Vict/75, and
B/Hong Kong/72 Influenza Antigens in Pre-Immunization Sera
Percent <1:10
No. A/NJ/76 A/Vict/75 B/HK/72
Age Sex Tested % % %
18-25 F 46 100 32.6 63.0
M 70 98.5 45.7 52.8
116 99.1 40.5 56.9
26-35 F 44 95.4 68.1 63.6
M 33 78.8 63.6 54.5
77 88.3 66.2 59.7
36-59 F 39 64.1 74.3 51.3
M 30 43.3 66.6 56.7
69 55.0 71.0 53.6
>60 F 5 0 40 60
M 4 0 75 100
9 0 77.7 77.7
Totals F 134 84.3 56.7 59.7
M 137 78.8 55.4 55.4
271 78.6 56.0 57.6
persons receiving monovalent A/ New Jersey/ 1976 vaccine and from 47 persons
receiving bivalent (A/New Jersey/ 1976 and A/Victoria/ 1975, containing 200 CCA
units of each vaccine) vaccine were tested simultaneously for antibody responses by
the HI test. Table S gives the detailed results: 78.3 percent of persons receiving
monovalent swine flu vaccine showed a four-fold or greater rise in antibody titer to
the vaccine strain. The response rate increased with age, risingfrom 75 percent in the
18-25 age group to 85 percent in the 36-59 year old group. No significant difference
in antibody responses was seen between 190 persons without pre-existing swine flu
antibody and 32 persons with pre-existing antibody. Four-fold or greater rises to
A/Victoria/ 1975 antigen were found in 16.3 percent of persons receiving only
monovalent A2/NJ/ 1976 vaccine virus, presumably due to antigenic cross-reactions.
Sera from 2 persons showed a rise to B/Hong Kong/ 1972 antigen, possibly
representing early examples of the B/Hong Kong outbreak which followed shortly
thereafter. The response to the bivalent vaccine in the 47 persons tested was poor:
only 51 percent showed a significant rise to A/New Jersey/ 1976 antigen and 25.5
percent to A/Victoria/ 1975 antigen both of which were present in the vaccine.
An analysis of responses to monovalent vaccine by sex and prior antibody status is
presented in Table 6. No consistent differences in response rate to the vaccine virus
were seen in the presence or absence ofpre-existing antibody. However, 21 percent of
males showed a rise to A/Victoria/ 1975 antigen which was not included in the
vaccine as compared with only 7.8 percent ofthefemales; the greater response rate in
males was higher whether pre-existing antibody to A/Victoria/75 was present or not.
Males may have received an A/Victoria vaccine while in military service and this
response may represent a cross reaction "booster" effect.
An analysis ofvaccine responses by geometric mean antibody titer (GMT) pre and
post immunization is summarized in Table 7. The results paralleled those measured
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TABLE 5
Percent Showing Four-fold or Greater Antibody Responses to Monovalent and Bivalent Vaccine
According to Pre-Vaccine Antibody Status against the Test Antigen
A/New Jersey/ 1976 A/Victoria/ 1975
Pre-Vaccine % with % with
Vaccine Age Titer* No. four-fold rise No. four-fold rise
Monovalent I
(A/NJ/76) 18-25 <10 103 74.7 38 34.2
>10 1 (100) 66 12.1
104 75.0 104 20.2
26-35 <10 56 80.3 41 12.2
>10 9 66.6 24 8.3
65 78.5 65 12.0
36-59 <1O 31 90.3 41 9.7
>10 22 77.2 12 8.3
53 84.9 53 9.4
Total <10 190 78.9 120 18.3
>10 32 75.0 102 13.7
222 78.3 222 16.2
Bivalent
(A/NJ/76 + 16-59 <10 30 56.6 22 27.2
A/Vict/75) >10 8 50.0 16 25.0
38 55.2 38 26.3
>60 <10 0 0 6 50
>10 9 33.3 3 0
9 33.3 9 33.3
Total <10 30 56.6 28 32.1
>10 17 41.1 19 15.8
47 51.0 47 25.5
*To test antigen
TABLE 6
H.I. Antibody Responses to Monovalent A/NJ/76 Vaccine by Sex
Percent with
Vaccine Pre-existing No. Four-fold Response
Given Sex Antibody* Tested A/NJ/76 A/Vict/75
Mono- F <10 91 79.1 8.9
Valent >10 12 83.3 6.3
103 79.6 7.8
M <10 99 78.7 26.5
>10 20 70.0 14.5
119 77.2 21.0
*To the antigen used in the testINFLUENZA IMMUNIZATION IN YALE COMMUNITY 173
TABLE 7
Geometric Mean Antibody Titers* (GMT) Before and After A/NJ/76 Vaccine
GMT to Antigen Strains
Vaccine Age No. State A/NJ A/Vict. B/HK
Monovalent 18-25 103 Pre 5.0 10.5 8.3
Post 31.2 18.0 9.3
26-35 65 Pre 5.6 7.2 8.3
Post 50.6 10.5 9.8
35-59 53 Pre 8.5 6.2 7.2
Post 136.8 8.3 8.4
Bivalent >60 9 Pre 45.6 7.9 5.8
Post 100.8 1.5.9 8.5
High Risk** 38 Pre 6.7 7.3 6.4
Post 31.6 14.4 7.1
*For the purposes of calculation of the GMT a titer of 1:5 was assigned to sera with a titer <1:10.
**High risk included persons with chronic pulmonary, cardiac, and metabolic disease.
by four-fold antibody increases: the highest post-immunization titers were attained in
the older age group. In the<25 year old age group receiving monovalent vaccine the
average GMT never reached the 1:40 titer above which re-infection is rare[3]. Cross-
reacting antibody increases to A/Vict/72 antigen occurred with increasing age. The
GMT response to A2/New Jersey/ 1976 was satisfactory in 9 persons over 60
receiving it but poor in 38 special risk persons under age 60. A poor response in both
age groups was also seen to the A2/Victoria/ 1975 antigen contained in the bivalent
vaccine. Little increase in GMT to B/Hong Kong occurred after monovalent or
bivalent vaccine since it was not included in either preparation.
The percent of persons attaining the presumably protective titer of> 1:40 post-
vaccination varied with age (Table 8). The> 1:40 titer was achieved in 51.9 percent of
TABLE 8
Percent at >1 1:40 H.I. Titer for A/NJ/76 Pre and Post Monovalent or Bivalent Vaccine
Age Vaccine No. Percent at
Vaccine Group Status Tested >1:40 to A/NJ/76
Monovalent 18-25 Pre 104 0
Post 104 51.9
26-35 Pre 65 0
Post 65 63.1
36-59 Pre 53 7.5
Post 53 90.6
Total Pre 222 1.8
Post 222 64.4
Bivalent 16-59 Pre 38 5.2
Post 38 44.7
60+ Pre 9 66.6
Post 9 100.0
Total Pre 47 17.0
Post 47 55.3EVANS AND KRAUS
the <25 age group, in 63.1 percent of the 26-35 year old age group, and in 90.6
percent of the 36-59 year old age group after one injection ofA/ NJ / 76 monovalent
vaccine. Overall 64.4 percent ofthe titers were at this level or higher. A poor response
was seen in the 38 persons in the high risk group, age 16-59, that received bivalent
vaccine-only 44.7 percent reached a level of> 1:40.
DISCUSSION
Approximately 19 percent of the 30,000 persons age 15 to 60 in the Yale
community, received monovalent A/New Jersey/ 1976 vaccine byjet injection on the
3 days of the mass immunization program; an additional 1674 doses of bivalent
vaccine were given to high risk groups. Influenza assessment data from the National
Influenza Center at CDC indicate that by Feb. 2, 1977, 56.52 percent of persons 18
years and over in Connecticut had been immunized, much above the national average
of 31.63 percent [4]. The reason for the lower response rate in the Yale community is
not clear. Some persons may have received vaccine after the mass campaign was over
or through other health services. While one might anticipate a higher level of health
consciousness in a University community, skepticism as to the possibility of an
outbreak or as to the effectiveness of the vaccine may also be higher in a University
community than the average Connecticut community.
The reaction rates to the monovalent vaccine were much higher than the 2-5
percent level expected on the basis offield trial data [5-8]. Complaints of a sore arm
at the site ofthejet injection occurred in 71.2 percent ofthe recipients and 5.9 percent
judged the reaction as severe. Headache was complained of in 23.4 percent of the
total group, muscle aches in 22.6 percent, chilliness in 13.4 percent, and fever or
feverishness in 9.7 percent; these reactions werejudged as severe in less than 2 percent
except for headache which was reported as severe in 4.2 percent. The frequency,
severity, and duration of the reactions to the swine flu vaccine were probably not of
sufficient magnitude to deter future use of a similar vaccine should a clear-cut need
exist.
All reactions to A/NJ/76 vaccine were reported more commonly by women of all
ages than by men. Whether this difference had a biologic basis, such as smaller
subject size in relation to dose, or represented a greater subjective perception of
discomfort is not known. Certainly the higherfrequency ofsore arms inwomen could
well reflect a smaller muscle mass.
A decreasing rate of side reactions to the vaccine occurred withincreasingage and
was observed in both sexes. The presence ofpre-existingantibodyto thevaccine virus
may account for a lower reaction rate, but since the reporting card was submitted
anonymously it was not possible to correlate the frequency of side reactions with the
presence or absence of antibody. However, it is consistent with the overall age
distribution of pre-existing antibody.
Antibody tests on 213 sera obtained at the time of immunization from the 18-59
age group indicated that 78.6 percent lacked A/New Jersey/ 1976 antibody at a titer
of 1:10 or higher, 56.0 percent lacked A/Victoria/ 1975 antibody, and 57.6 percent
lacked B/Hong Kong/ 1972 antibody. The percent of swine influenza susceptibles
varied markedly with age. Antibody was absent in 99.1 percent of the 18-25 year
olds, in 88.3 percent of those aged 26-35, and in 55 percent of those 36-59 years
old. These figures are generally comparable to those summarized by Hattwick et
al. [5] from five community surveys around the country (1961-1976) although
the 55 percent susceptibility rate in persons over 30 was greater than in other
studies.
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The overall antibody response to a single dose of monovalent A/NewJersey/ 1976
vaccine (Merrell-National, Cincinnati, Ohio) containing 200 CCA units per dose was
fairly good: 78.9 percent ofthe recipients showed a four-fold or greater antibodytiter
rise to the homologous antigen 3-4 weeks later, the geometric mean antibody titer
rose from 1:5.9 to 1:53.1; 64.4 percent ofthose vaccinated had levels of 1:40 or higher
post immunization. Antibody rises occurred more commonly in those age 36-59 (84.9
percent) than in those in the .25 age group (75.5 percent). The geometric mean an-
tibody titer after immunization was also much higher in the older (1:136.8) than the
younger (1:31.2) group. Despite this, the antibody response rate was similar in 32
persons with pre-existing A/New Jersey/ 1976 antibody (75.0 percent) as compared
with 190 persons lacking this antibody (78.9 percent). While the antigen was not
included in the vaccine, antibody rises to A/Victoria/ 1975 occurred in 16.3 percent
recipients of the monovalent A/NJ/76 vaccine presumably as a result of cross-
reactions. Only 2 persons showed an antibody increase to B/Hong Kong/ 1972
antigen which was not included in the vaccine; these 2 may have been early victims of
a B/HK outbreak which followed later.
These antibody response rates to the 200 CCA units of Merrell-National monova-
lent vaccine confirm the results of preliminary field trials [6] although our response
rate (75.0 percent) was higher than theirs (49 percent) in persons under 25 years old.
As no swine influenza epidemic occurred it was not possible tojudge the effectiveness
of the vaccine against a natural challenge. However, ifan outbreak ofswine influenza
had occurred late in the fall of 1976 it would have found only 20 percent of the Yale
community immunized in the mass campaign. In the 18-25 age group who lacked
swine influenza antibody prior to immunization only 52 percent developed a
protective level of HI antibody >1:40 from immunization. A booster dose would
certainly have been required in this group in the face ofanepidemic. In the 26-35 age
group the percent with antibody titers at 1:40 or higher rose from none pre-
immunization to 63 percent post-immunization; a booster dose might also have been
desirable in the face of a large epidemic. In the 35-59 year old age group the pre-
immunization antibody prevalence at> 1:40 was 7.5 percent and post-immunization
was 90.6 percent. Booster doses would not have been needed in this group. Clearly a
virulent influenza strain like that of 1918 could have produced a disastrous epidemic
in a population with so many susceptibles remaining in the younger age groups. if
such an epidemic had actually occurred it is likely that the mass immunization
campaign would have beenvigorously pursued and expanded despite the problems of
high reaction rates, poor antibody response in the younger age group, and the rare
occurrence of the Guillain-Barre syndrome [9].
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